Nephrology
Conference Coverage
SGLT2 inhibitors cut AFib risk in real-word analysis
Observational data add to a growing link between SGLT2 inhibitor treatment and atrial fibrillation prevention in people with type 2 diabetes.
News
ADA updates on finerenone, SGLT2 inhibitors, and race-based eGFR
ADA has made an interim change to its latest Standards of Medical Care, an update based on trial evidence and consensus about finerenone, SGLT2...
News
Mixing BP meds with NSAID may be ‘triple whammy’ for kidneys
In the absence of additional risk factors, there was no indication of an elevated risk for AKI when an ACE inhibitor and NSAID are combined.
Latest News
Empagliflozin scores topline win in EMPA-KIDNEY trial
Researchers stopped the 6,600-patient EMPA-KIDNEY trial sooner than expected because it positively met prespecified efficacy criteria in a trial...
Latest News
Antiseptic as good as antibiotics for preventing recurrent UTI
Using methenamine hippurate as an alternative could play an important role in helping to tackle the global problem of increasing antibiotic...
News
Community genetic testing prompts behavior change in patients
“These two measurements – the change in blood pressure and increased kidney function tests – act as hallmarks for detecting beneficial lifestyle...
Case Reports
Pheochromocytoma: An Incidental Finding in an Asymptomatic Older Adult With Renal Oncocytoma
A high index of suspicion for pheochromocytoma is necessary during the workup of secondary hypertension as untreated pheochromocytoma may lead to...
Case Reports
Cisplatin-Induced Acute Kidney Injury and Renal Salt Wasting Syndrome
A treatment strategy that incorporates both water restrictions and sodium supplementation may be appropriate when differentiating between...
Conference Coverage
Advanced CKD doesn’t derail empagliflozin in EMPEROR-preserved
Study shows empagliflozin led to a consistent, significant relative risk reduction compared with placebo in the primary endpoint.
News
SGLT2 inhibitors for diabetes: No link to fractures in older adults
Analysis of Medicare data supports findings from younger adults that use of the drug class does not appear to raise fracture risk.